Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452815 · ClinicalTrials.gov registry record · Phase 2
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
A Phase 2 study, sponsored by Tranzyme.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT01452815 is a Phase 2 study that has completed, run by Tranzyme. The registered enrollment target is 201 participants.
The verdict
NCT01452815, a Phase 2 study, has completed, sponsored by Tranzyme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active drug), administered once-daily for 12 weeks, in diabetic subjects with symptoms associated with gastroparesis.
Interventions
- DRUG Placebo
- DRUG 10mg TZP-102
- DRUG 20mg TZP-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01452815
The ClinicalTrials.gov registry entry for NCT01452815 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tranzyme, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01452815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01452815 about?
NCT01452815 is a clinical study titled "Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis". The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active drug), administered once-daily for 12 weeks, in diabetic subjects with symptoms associated with gastrop...
What is the current status of trial NCT01452815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2011-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01452815?
The interventions under investigation include: Placebo (DRUG), 10mg TZP-102 (DRUG), 20mg TZP-102 (DRUG).
Who is sponsoring clinical trial NCT01452815?
This trial is sponsored by Tranzyme, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.